Migraine prevention drug erenumab (Aimovig) appeared safe and effective in patients both with and without aura, pooled trial data showed. In a post hoc secondary analysis of four randomized clinical ...

Erenumab treatment has been associated with reductions in migraine frequency and improvements in health-related quality of life that were maintained for at least 5 years, according to the results of ...

After initiating erenumab, patients with predominately refractory chronic migraine had fewer headache/migraine days per month and outpatient visits, according to study results published in Neurology ...

Please provide your email address to receive an email when new articles are posted on . Flushing and erythema were reduced in patients using erenumab, a CGRP receptor antagonist. Adverse events were ...

Credit: Shutterstock. The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up ...

Discover comprehensive details about Erenumab-aooe, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Migraine headaches affect thousands of Americans and millions worldwide. There are several medications that are being prescribed for migraines and for many these do not work well. In a couple of ...

A GROUNDBREAKING new migraine drug is set to hit Britain’s shelves after European health officials granted it a licence on July 30, 2018. Here’s everything you need to know about the preventative ...

• Erenumab-aooe injection comes as a single-dose prefilled syringe or prefilled autoinjector and should be administered subcutaneously or just under the skin. • Erenumab-aooe injection should be ...

Erenumab was not effective in reducing pain intensity in patients with trigeminal neuralgia, researchers reported in Lancet Neurology. Trigeminal neuralgia is a severe facial pain disorder that is ...

Erenumab (Aimovig) significantly cuts migraine frequency in patients with migraine who have a history of aura, a new analysis shows. The human anti-CGRP receptor monoclonal antibody erenumab is ...